REG - BioPharma Credit PLC - Appointment of New Director

Biopharma CreditAnnouncement

Thu 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2830Ta&default-theme=true

RNS Number : 2830T  BioPharma Credit PLC  31 July 2025

31 July 2025

 

BIOPHARMA CREDIT PLC

(THE "COMPANY")

Appointment of New Director

 

The Board of Directors of the Company, as part of its proactive succession
planning, is pleased to announce the appointment of Nigel Reynolds as a
non-executive Director with effect from 1 January 2026, following his
retirement from PwC on 31 December 2025.  Mr Reynolds will, after a
transition period, take over as chair of the Company's Audit and Risk
committee.

Mr Reynolds has 34 years of accounting and finance experience advising both
listed and private companies.  He has been a partner at PwC for 20 years
specialising in audit, transaction services and capital markets work.  During
his time at PwC, he led its London Assurance practice for 5 years, led the
private equity portfolio company practice and was the relationship partner for
various UK listed and international companies including companies in
healthcare and investment trusts.  Over his career he has also advised
companies on strategy, M&A, internal audit and tax and has overseen
technology, sustainability, and other large projects for PwC clients.

There are no other details required to be disclosed under LR 9.6.13R (1) to
(6) of the Financial Conduct Authority Listing Rules.

 

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGFNRGGGKZM